Previous evidence reveals that overexpression of FOXM1 has been implicated in proliferation, metastasis, epithelial-mesenchymal transition (EMT), chemoresistance, and poor prognosis of cancers [8,34,35]. This evidence concerns the gene FOXM1 and cancer.